Breast cancer

【Product name】Kadcyla

[English common name]Ado-trastuzumab emtansine

[Chinese common name]Ado-trastuzumab

[English name]

[Chinese other name]

[indications] metastaticBreast cancer: This product is suitable for HER2-positive metastatic breast cancer: metastatic breast cancer that has received one or more chemotherapy regimens as a single drug; combined with paclitaxel or docetaxel for metastasis without chemotherapy Breast cancer patients.
Adjuvant therapy for breast cancer: This product is suitable for the adjuvant treatment of HER2 overexpressing breast cancer after surgery, adjuvant chemotherapy with anthracyclines and radiotherapy (if applicable).
Metastatic gastric cancer: This product is combined with capecitabine or 5-fluorouracil and cisplatin for patients with metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have not received HER2 overexpression for the treatment of metastatic disease.
Trastuzumab can only be used in patients with metastatic gastric cancer with HER2 overexpression, and HER2 overexpression is defined as IHC3+ or IHC2+/FISH+ results obtained using validated assays.

[Usage and Dosage] Please fully dilute the reconstituted drug after the requirement of 'infusion preparation'.
Do not push or push the vein quickly.
HER2 testing should be performed prior to treatment with this product.
The use of any other biological substitutes requires the consent of the prescribing physician.
This product should be administered by intravenous infusion.
Metastatic breast cancer
Weekly dosing schedule
Initial load dose: It is recommended that the initial load of this product is 4mg/kg. Intravenous infusion for more than 90 minutes.
Maintenance dose: This product is recommended to be used at a dose of 2 mg/kg per week. If the initial load is tolerable, the dose can be infused intravenously for 30 minutes. Maintain treatment until disease progression.

[Storage] Store in the refrigerator (2 ° C – 8 ° C).

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Perjeta

[English common name]Pertuzumab

[Chinese common name]Pertuzumab

[English name]Ertuzumab [INN], Omnitarg, rhuMAb 2C4

[Chinese other name]

[Indications] PERJETA is a HER2/neu receptor antagonist that should be combined with trastuzumab and docetaxel. The treatment population is: no previous anti-HER2 treatment or chemotherapy. HER2+ metastaticBreast cancerpatient.

【Dosage】
(1) Intravenous infusion only. Do not administer intravenous bolus or bolus.
(2) The initial dose was 840 mg, and the intravenous infusion was completed over 60 minutes. Thereafter, 420 mg every 3 weeks, intravenous infusion over a period of 30 to 60 minutes.

[Storage]Protected from light and stored in the refrigerator at 2 ° C to 8 ° C (36 ° F to 46 ° F).

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Halaven

[English common name]Eribulin

[Chinese common name]Eriblin mesylate

[English name]Eribulin Mesilate

[Chinese other name]Erebrin mesylate

[Indications] for the treatment of metastasis that has been treated with at least 2 chemotherapy regimensBreast cancerPatients, and the chemotherapy regimen should include an anthracycline or a taxane.

【Dosage】Eribulin mesylate was dissolved in a 5% by volume aqueous solution of ethanol at a concentration of 0.5 g/mL, usually at a dose of 21 days (1 day): 1.4 mg at 1 d and 8 d M2, intravenous injection lasted 2-5 min.

[Storage] From a microbiological point of view, the product should be used immediately unless the opening method eliminates the risk of microbial contamination. If not used immediately, the storage time and conditions in use are the responsibility of the user.
If HALAVEN is not used immediately as an undiluted solution in a syringe, it should not be stored for more than 4 hours at 25 ° C and ambient light, or 24 hours at 2 ° C – 8 ° C.
A diluted solution of HALAVEN (0.018 mg / ml to 0.18 mg / ml eribulin in sodium chloride 9 mg / ml (0.9%)) should not be stored at 2 ° C – 8 ° C for more than 24 hours unless Dilution is carried out under controlled and effective aseptic conditions.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Alkeran

[English common name]Melphalan

[Chinese common name]Melphalan

[English name]Melphalan HCl, Melphalan 2HCl, l-phenylalanine mustard

[Chinese other name]Melfal, Melphalan, cancer Kyan, Milfair

[Indications] This product can be used with a variety of tumors, in single chemotherapy and combination chemotherapy,Multiple myelomaThe drug of choice. CorrectSpermato cell tumor,Breast cancer,Ovarian cancer,Chronic leukemia,Polycythemia vera,Malignant lymphoma,Late childhood neuroblastoma,Thyroid cancereffective. Arterial infusion for the treatment of limb malignancies such as malignant melanoma, soft tissue sarcoma and osteosarcoma has a good effect, even for the treatment of certain autoimmune diseases and to prevent rejection during organ transplantation.

【Dosage】
Multiple myeloma:
A typical dose is 0.15 mg per kilogram of body weight per day, taken in four divided doses, and repeated for six weeks. Prolonged treatment for those who respond to treatment will not change the effect. The combination of melphalan and prednisone may be more effective than single use.
Ovarian adenocarcinoma:
A typical treatment regimen is 0.2 mg per kilogram of body weight per day for five days, repeated every 4 to 8 weeks or when the peripheral blood is restored; the dose should be reduced when bone marrow toxicity occurs.
Advanced breast cancer:
Oral melphalan daily 0.15 mg per kilogram of body weight or 6 mg per square meter of body surface area for a total of 5 days, repeated treatments every six weeks, can also be treated with intravenous melphalan.
True erythrocytosis:
Induction of remission, use 6 to 10 mg daily for 5 to 7 days, then 2 to 4 mg per day until the symptoms can be satisfactorily controlled. The maintenance dose can be 2 to 6 mg per week. Care must be taken during the patient. The hematology control is performed on the ground, and the dose is appropriately adjusted based on the blood cell count result.
Patients with renal insufficiency:
Based on current pharmacokinetic data, oral melphalan is not recommended for patients with moderate to severe renal insufficiency, but the initial dose should be carefully reduced.

[Storage]Store in a dark, cool, dry place.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.